Managing Partner, Averin
Boston, MA
Joined February 2012
- Tweets3K
- Following231
- Followers1.6K
- Likes9
Treasury’s draft COINS rule treats a Chinese biosimilar plant like a hypersonic missile program.
It won’t slow China biotech. It just ensures Americans don’t own any of it.
Licensing isn’t covered, so the molecules still flow West. Non-US capital takes the upside.
Really enjoyed the conversation with @DWeisburd! Always fun talking about building companies!
#innovation #ai @averincapital #sustainability #Health #Startups
🚀 What does it REALLY take to build 7 biotech unicorns? 🦄
🎙️ I just dropped an exclusive podcast episode featuring @DavidBerry26, famously called the “Elon Musk of Biotech.” If you want to understand how he turned bold ideas into billion-dollar companies—and why perseverance, curiosity, and being willing to be wrong are the secret sauce—this is a must-listen. 👂✨
👀 Curious about:
- The pivotal moments when startups pivot or persevere? 🔄
- What it’s like to build $1B+ companies that transform healthcare? 🌍
- Why culture and mission matter more than hours worked? ⏰💡
- How founders and investors align to build big outcomes vs. simply incremental ones? 💼🤝
This episode is packed with insights for entrepreneurs, investors, and anyone passionate about the future of health and tech. Don’t miss it!
🎧 Listen now and join the conversation 👇
#Biotech #Podcast #Innovation #Entrepreneurship #Startups #VentureCapital #Leadership #HealthTech #Investing
Link to Podcast in Comments Below 👇
Congrats to the @freenome team for their recent publication in JAMA on their pivotal study.
prnewswire.com/news-releases…
#liquidbiopsy #ai #futureofhealth #innovation @averincapital
I’ve always fascinated with the bias against the transformative power of technology in drug discovery.
Looking forward to hosting the webinar "Activated Intelligence: AI's Leap from Algorithms to Impact" next week with Andrew Hopkins of Xyme, Jared Saul of
@awscloud, and Andrew Dobry of BiOptic.
#ai #innovation #futureofmedicine @averincapital
Great article by @BenTomaszewski on employer sponsored health benefits. With costs as a clear catalyst, the move towards integrated care and AI-driven efficiencies has the potential to deliver better outcomes for patients with less financial burden.
averincapital.com/insights/t…
#innovation #futureofmedicine #ai @averincapital #healthcare
Per the WSJ today: 90% of drugs are generics with thin margins. Reform requires innovation in the middle of the pharmaceutical supply chain. This is an area where AI can lead to step function changes and ideally better outcomes for patients while continuing to foster the creation of new innovative medicines.
wsj.com/opinion/how-to-reduc…
#innovation #ai @averincapital #futureofmedicine #drugdevelopment #drugdiscovery
Great article by Averin's Eric Berry on digital twins. As we think about the need to make clinical trials faster, less expensive, and more predictable, digital twins offer a the potential for a step function change in addition to the rest of what they can do for healthcare.
averincapital.com/insights/d…
#innovation #clinicaltrials #drugdevelopment #ai #digitaltwins @averincapital's @ezberry
Great article by Rich Yang of Biolinq on the potential for devices coupled to drugs to transform care. We are just at the beginning of the era of measured self and the potential to unlock better care and outcomes-including from what drugs would do independently.
weforum.org/stories/2025/01/…
#biosensors #innovation #ai #diabetes #patientcare #measuredself #longevity @averincapital
Whenever there is a challenge presented, I prefer to think about what are the opportunities that are created. The impact of the MFN is of course far reaching, but it also strikes me that this could be huge catalyst AI drug discovery and development. Increasing productivity by reducing cost and time while increasing probability of success can create a different economic framework.
axios.com/2025/05/12/trump-d…
It was great to join Frank Nestle on @bios_community to talk about the growing role of AI in bio
Roundtable ✨ - AI in Bio w/ Frank Nestle & David Berry
Hear from Frank Nestle (Global Head of Research & CSO @sanofi) and @DavidBerry26 (General Partner @ @FlagshipPioneer / Founder & CEO @ValoHealth) on the future of AI in bio...
ow.ly/VzQm50Oz9lf
David Berry retweeted
Today @SeresTx marked an important milestone in the development of drugs that leverage millions of years of coevolution between microbes and humans for the prevention or treatment of diseases. ir.serestherapeutics.com/new…
David Berry retweeted
Today we announced that @ValoHealth is participating at upcoming events this month and next. Will we see you there? valohealth.com/press/valo-he… @DavidBerry26 @GraemeBellTx @DAVIDMO39701496
At @ValoHealth , we are driven to make better drugs faster - not just for ourselves to but to enable others. We are proud to enable @PioneeringMeds through Logica, a joint offering with @CharlesRiverLa1
ir.criver.com/news-releases/…
Speaking with @FlagshipPioneer during #jpm2023--I'm always inspired by the great work the team @ValoHealth does in pioneering a new frontier for drug discovery and development flagshippioneering.com/stori…
It was great joining @NYSE for their The Cure(ious) series during #jpm2023. I credit Bob Langer with the quote below, which has been a driver for me especially as in thinking about companies like @ValoHealth and our aspirations to make better drugs for patients, faster
The best advice The Cure(ious) @DavidBerry26 of @ValoHealth received?
“All problems are equally hard, so go after the big ones. That’s the motivation for how I want to spend my time; ultimately if we can deliver that change and deliver that impact, it will matter for society.”
David Berry retweeted
Valo's CEO & Founder @DavidBerry26 is presenting at the @jpmorgan Healthcare Conference on Tuesday, January 10th at 2:30 PM PT. Come find the Valo team to learn more about how we are transforming drug discovery valohealth.com/investors
Congratulations to Frank Lee and Forma Therapeutics on their accounted acquisition by Novo Nordisk! When we @ValoHealth acquired the R&D capabilities of Forma, we saw the power to make distinctive drugs like etavopivat. reuters.com/markets/deals/no…
By including the capabilities of Forma Therapeutics with @ValoHealth's Opal Computational Platform, where the power of AI can enable accelerated learning, we created closed loop drug design capabilities now part of our Logica offering with Charles River Labs.